Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence

  • Technology appraisal guidance
  • TA810
  • Published: 

History

Documents created during the development process.

Expected publication

Final draft guidance

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators